Pemeriksaan Cea dan M2PK Sebagai Tes Skrining Pada Kanker Kolorektal
DOI:
https://doi.org/10.26630/jak.v10i1.2720Keywords:
Kanker Kolorektal, CEA, M2PK, Tes SkriningAbstract
Kanker memiliki ciri mempertahankan sinyal proliferatif, menghindari penekan pertumbuhan, terjadi invasi dan metastasis, menginduksi angiogenesis, memungkinkan replikatif yang immortal, dan melawan kematian sel. Kanker kolorektal (CRC) merupakan hubungan kompleks dari sel tumor, sel non-neoplastik, dan sejumlah besar mikroorganisme. Deteksi dini pada awal lesi dapat menurunkan mordibitas dan mortilitas keganasan, sehingga penting dilakukan skrining. Pemeriksaan CEA dan M2PK dapat dilakukan sebagai tes skrining yang dilakukan di laboratorium. Beberapa Laboratorium sering kali hanya melakukan 1 pemeriksaan saja seperti CEA tanpa M2PK. Penelitian ini bertujuan untuk mengetahui perbedaan antara pemeriksaan CEA dan M2PK sebagai tes skrining kanker kolorektal. Penelitian ini dilakukan menggunakan metode komparatif. Penelitian dilakukan pada bulan Maret-Mei 2020 di Laboratorium Multilab Rawamangun. Sampel penelitian berasal dari 30 orang subjek yang dipilih berdasarkan kriteria harus melakukan pemeriksaan CEA dan M2PK secara bersamaan. Hasil uji statistik menggunakan uji Mann-Whitney diperoleh hasil p value 0,000. Hasil analisa tersebut menujukkan adanya perbedaan yang signifikan antara pemeriksaan CEA dan M2PK sebagai diagnosis kanker kolorektal. Pemeriksaan CEA dan M2PK dapat digunakan sebagai tes skrining awal pada pemeriksaan kanker kolorektal.
References
Bénard, F., Barkun, A. N., Martel, M., & Renteln, D. Von. (2018). Systematic review of colorectal cancer screening guidelines for average-risk adults : Summarizing the current global recommendations. 24(1), 124–138. https://doi.org/10.3748/wjg.v24.i1.124
Dabbous, H. K., Mohamed, Y. A. E., El-folly, R. F., & El-talkawy, M. D. (2018). Evaluation of Fecal M2PK as a Diagnostic Marker in Colorectal Cancer.
De Rosa, M., Pace, U., Rega, D., Costabile, V., Duraturo, F., Izzo, P., & Delrio, P. (2015). Genetics, diagnosis and management of colorectal cancer (Review). Oncology Reports, 34(3), 1087–1096. https://doi.org/10.3892/or.2015.4108
El, M., Ibrahim, T., Mohamed, M. A., Elawady, M. A., & Hala, A. (2018). The Fecal M2-PK As A Novel Biomarker for Screening of Cancer Colon. The Egyptian Journal of Community Medicine, 36(3), 93–102. https://doi.org/10.21608/ejcm.2018.16337
Gagnière, J., Raisch, J., Veziant, J., Barnich, N., Bonnet, R., Buc, E., Bringer, M. A., Pezet, D., & Bonnet, M. (2016). Gut microbiota imbalance and colorectal cancer. World Journal of Gastroenterology, 22(2), 501–518. https://doi.org/10.3748/wjg.v22.i2.501
Gao, Y., Wang, J., Zhou, Y., Sheng, S., Qian, S. Y., & Huo, X. (2018). Evaluation of Serum CEA, CA19-9, CA72-4, CA125 and Ferritin as Diagnostic Markers and Factors of Clinical Parameters for Colorectal Cancer. Scientific Reports, 8(1), 1–9. https://doi.org/10.1038/s41598-018-21048-y
Grady, W. M., Markowitz, S. D., & Hutchison, F. (2016). potential application to colorectal cancer screening. 60(3), 762–772. https://doi.org/10.1007/s10620-014-3444-4.The
Hall, C., Clarke, L., Pal, A., Buchwald, P., Eglinton, T., Wakeman, C., & Frizelle, F. (2019). A review of the role of carcinoembryonic antigen in clinical practice. Annals of Coloproctology, 35(6), 294–305. https://doi.org/10.3393/ac.2019.11.13
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646–674. https://doi.org/10.1016/j.cell.2011.02.013
Janosik, S. M. (2014). Porth’s Pathophysiology. In Lippincott Williams & Wilkins (Vol. 42, Issue 4).
Jemal, A., Bray, F., & Ferlay, J. (2011). Global Cancer Statistics. 61(2), 69–90. https://doi.org/10.3322/caac.20107.Available
Jia, J., Zhang, P., Gou, M., Yang, F., & Qian, N. (2019). The Role of Serum CEA and CA19-9 in Efficacy Evaluations and Progression-Free Survival Predictions for Patients Treated with Cetuximab Combined with FOLFOX4 or FOLFIRI as a First-Line Treatment for Advanced Colorectal Cancer. 2019.
Kontomanolis, E. N., Koutras, A., Syllaios, A., Schizas, D., Mastoraki, A., Garmpis, N., Diakosavvas, M., Angelou, K., Tsatsaris, G., Pagkalos, A., Ntounis, T., & Fasoulakis, Z. (2020). Role of oncogenes and tumor-suppressor genes in carcinogenesis: A review. Anticancer Research, 40(11), 6009–6015. https://doi.org/10.21873/anticanres.14622
Grossman, S.C., Porth, C.M. (2014). Porth's Pathophysiology Concepts of Altered Health States 9th Ed. Lippincot Wiliams and Wilkins.
Maulani, J. (2019). Aplikasi Kesehatan Menggunakan Metode Epidemiologi Skrining Tes Untuk Karyawan Cv.Annisa. Technologia, 10(1).
Meng, W. (2012). Serum M2-pyruvate kinase: A promising non-invasive biomarker for colorectal cancer mass screening. World Journal of Gastrointestinal Oncology, 4(6), 145. https://doi.org/10.4251/wjgo.v4.i6.145
Muñoz-Colmenero, A., Fernández-Suárez, A., Fatela-Cantillo, D., Ocaña-Pérez, E., DomÃnguez-Jiménez, J. L., & DÃaz-Iglesias, J. M. (2015). Plasma tumor M2-pyruvate kinase levels in different cancer types. Anticancer Research, 35(7), 4271–4276.
Permana, F., Budiono, B., & Farida, H. (2016). Hubungan Kadar Carcinoembryonic Antigen (Cea) Dan Albumin Serum Dengan Lokasi Kanker Kolorektal Studi Kasus Di Rsup Dr. Kariadi. Diponegoro Medical Journal (Jurnal Kedokteran Diponegoro), 5(4), 808–816.
Rigi, F., Jannatabad, A., Izanloo, A., Roshanravan, R., Hashemian, H. R., & Kerachian, M. A. (2020). Expression of tumor pyruvate kinase M2 isoform in plasma and stool of patients with colorectal cancer or adenomatous polyps. BMC Gastroenterology, 20(1), 1–7. https://doi.org/10.1186/s12876-020-01377-x
Schrijvers, D., Aapro, M., Zakotnik, B., Audisio, R., van Halteren, H., & Hurria, A. (2010). ESMO handbook of cancer in the senior patient. ESMO Handbook of Cancer in the Senior Patient, iii–193. https://doi.org/10.3109/9781841847481
Sithambaram, S., Hilmi, I., & Goh, K. L. (2015). The diagnostic accuracy of the M2 pyruvate kinase Quick stool test-A rapid office based assay test for the detection of colorectal cancer. PLoS ONE, 10(7). https://doi.org/10.1371/journal.pone.0131616
Tonus, C., Sellinger, M., Koss, K., & Neupert, G. (2012). Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: A meta-analysis. World Journal of Gastroenterology, 18(30), 4004–4011. https://doi.org/10.3748/wjg.v18.i30.4004
Vinay Kumar, Abdul K Abbas, J. C. A. (2013). Robbins Basic Pathology (9th ed.). ElsevierSaunders.
Widyasari, A., Tambunan, B.A., Budipramana, V. (2018). The Role Of Carcinoembryonic Antigen In Assessing The Success Of Surgical Treatment In Colorectal Cancer Based On Staging. Jurnal Indonesia, 21(3), 261–265. http://journal.unair.ac.id/download-fullpapers-IJCPML-12-3-08.pdf
Xu, X., Niu, M., Zhang, B., Chang, J., Su, F., & Wang, K. (2019). Clinical value of CEA and CA19-9 in colorectal cancer by Kaplan-Meier survival curve. 12(12), 13305–13310.
Downloads
Published
Issue
Section
License
Jurnal Analisis Kesehatan is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Based on a work at https://ejurnal.poltekkes-tjk.ac.id/index.php/JANALISKES.
